News Image

Propanc Biopharma Provides Shareholder Update

Provided By GlobeNewswire

Last update: Aug 25, 2025

MELBOURNE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced a shareholder update including recent corporate developments and forecast for 2025/26. As a result of completing a recent initial public offering and up-listing to Nasdaq, the Company is entering a transformational stage as it prepares for the advancement of its lead asset, “PRP”, to enter a Phase 1B, First-In-Human (FIH) study in 30 – 40 advanced cancer patients suffering from malignant solid tumors designed to identify the maximum tolerated dose (MTD) in 2026.

Read more at globenewswire.com

PROPANC BIOPHARMA INC

NASDAQ:PPCB (10/1/2025, 9:23:41 PM)

After market: 1.71 +0.01 (+0.59%)

1.7

0 (0%)



Find more stocks in the Stock Screener

Follow ChartMill for more